Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Retina Associates of Florida, P.A. | OTHER |
| Illinois Retina Associates | OTHER |
| Kresge Eye Institute | OTHER |
| Long Island Vitreoretinal Consultants |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bevacizumab | Active Comparator |
| |
| Ranibizumab | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravitreal injection of bevacizumab | Drug | 1.25 mg per dose, delivered monthly by intravitreal injection for six months |
|
| Measure | Description | Time Frame |
|---|---|---|
| change in central retinal thickness | central thickness is measured using optical coherence tomography (OCT) | six months compared to baseline |
| Measure | Description | Time Frame |
|---|---|---|
| change in best-corrected Snellen visual acuity | best-corrected Snellen visual acuity (BCVA) is the best visual acuity measured using a standard Snellen eye chart at 20 feet between (1) uncorrected vision, (2) vision with current eyeglasses or (3) pinholed visual acuity. | six months compared to baseline |
| change in fluorescein angiogram |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Retina Institute | St Louis | Missouri | 63110 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26431300 | Derived | Rajagopal R, Shah GK, Blinder KJ, Altaweel M, Eliott D, Wee R, Cooper B, Walia H, Smith BT, Joseph DP. Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study. Ophthalmic Surg Lasers Imaging Retina. 2015 Sep;46(8):844-50. doi: 10.3928/23258160-20150909-09. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012170 | Retinal Vein Occlusion |
| D008269 | Macular Edema |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D020246 | Venous Thrombosis |
| D013927 | Thrombosis |
Not provided
Not provided
| OTHER |
| Mid Atlantic Retina | OTHER |
| Retina Associates, Kansas City | OTHER |
| Massachusetts Eye and Ear Infirmary | OTHER |
Not provided
Not provided
Not provided
Not provided
| Intravitreal injection of ranibizumab (0.5 mg per dose) | Drug | 0.5 mg per dose, delivered monthly by intravitreal injection for six months |
|
fluorescein angiograms will measure area of peripheral nonperfusion. This will be interpreted by a designated physician at each testing center. |
| six months compared to baseline |
| D016769 |
| Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |